Collagen
This article was originally published in The Gray Sheet
Executive Summary
Firm receives conditional approval of an investigational device exemption to begin human studies with its Collagraft bone graft strip for the treatment of scoliosis, President and CEO Howard Palefsky announces at a May 10 session of the Alex. Brown investment conference in Baltimore. The study, which will be conducted by Collagraft marketing/clinical partner Zimmer, will include 224 subjects at 10 sites. The paste form of Collagraft was approved in May 1993 for use in long bone fractures and traumatic osseous defects, and the second generation solid strip form received approval in January